middle.news
Why Is CSL Delaying Its Seqirus Demerger Amid Market Challenges?
9:15am on Tuesday 28th of October, 2025 AEDT
•
Healthcare
Read Story
Why Is CSL Delaying Its Seqirus Demerger Amid Market Challenges?
9:15am on Tuesday 28th of October, 2025 AEDT
Key Points
FY26 revenue growth guidance cut to 2-3% from 4-5%
NPATA growth forecast lowered to 4-7% due to US vaccine market softness
Seqirus demerger delayed until market conditions improve
Targeting over $500 million annual pre-tax cost savings by FY28
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE